Biochem/physiol ActionsLFM-A13 is a potent and selective inhibitor of Bruton′s tyrosine kinase (BTK)
LFM-A13 is an inhibitor of the nonreceptor tyrosine kinase Bruton′s tyrosine kinase (Btk), a new molecular target for treatment of B-cell lymphoma and autoimmune disorders. LFMA13 inhibited recombinant BTK with an IC50 value of 2.5microM with 100-fold lower inhibitory activity against a number of other protein kinases including JAK1, JAK2, EGFR, IRK, IKK, and CDK1, 2 and 3, as well as several other related kinases
Features and BenefitsThis compound is a featured product for Kinase Phosphatase Biology research.
Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at
sigma.com/discover-bsm.